New hope for women with Hard-to-Treat breast cancer: drug combo trial launches

NCT ID NCT06954480

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for women with a type of advanced breast cancer called triple-negative breast cancer that does not have the PDL1 protein. It tests whether adding an immunotherapy drug (durvalumab) to a targeted chemotherapy (datopotamab deruxtecan) works better than the chemotherapy alone. About 140 participants will be randomly assigned to one of the two treatments. The goal is to see if the combination helps keep the cancer from growing longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Barts Cancer Institute, Centre of Experimental Cancer Medicine
NOT_YET_RECRUITING

London, EC1M 6BQ, United Kingdom
Barts Health NHS Trust
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.